This clinical trial tests how well the multilevel action toward colorectal cancer and hepatitis C education and screening (MATCHES) intervention works to promote concurrent hepatitis C virus (HCV) and colorectal cancer (CRC) screening among federally qualified health center (FQHC) patients ages 45-75. CRC and liver cancer are two of the leading causes of United States cancer mortality. Screening is an essential step in the care continuum for both CRC and HCV, the latter which is a main contributor to liver cancer. Yet, CRC and HCV screening uptake remains suboptimal, especially among FQHC patients. Compared to other primary care settings, FQHCs serve a higher proportion of patients from disproportionately affected communities including individuals who are under- and uninsured and individuals from racial/ethnic minority groups. Multiple disparities in CRC and HCV screening rates exist based on income and insurance access. MATCHES features strategies that target the system-, provider-, and patient-levels. System-level strategies include a customized electronic health record best practice alert and standard operating procedures for follow-up care. Provider-level strategies include a training session and feedback on screening rates. Patient-level strategies include a theory-informed educational booklet about both CRC and HCV screening in English or Spanish and facilitated fecal immunochemical testing and HCV screening. MATCHES may increase CRC and HCV screening and reduce CRC and liver cancer mortality among patients aged 45-75.
Additional locations may be listed on ClinicalTrials.gov for NCT06745895.
Locations matching your search criteria
United States
Florida
Tampa
Moffitt Cancer CenterStatus: Active
Contact: Shannon M. Christy
Phone: 813-745-8840
PRIMARY OBJECTIVES:
I. Test the effectiveness of the MATCHES intervention to promote both CRC and HCV screening at 12 months post-intervention among FQHC patients ages 45-75.
II. Examine mediators and moderators of MATCHES intervention effect.
III. Explore implementation outcomes and identify implementation barriers and facilitators.
OUTLINE: Clinic sites within the FQHC are randomized to start MATCHES intervention delivery in 1 of 2 waves and providers and patients are assigned to receive the interventions at the time during which their clinic was randomized.
WAVE 1: Clinic sites receive a customized electronic health record best practice alert pairing CRC and HCV screening with direct test ordering option and standard operating procedures for follow-up care for patients with an abnormal screening result and in need of treatment. Providers receive training and semi-annual feedback on CRC screening and HCV screening rates during months 7-12. Patients receive a combined education booklet with information about CRC/CRC screening and HCV infections/liver cancer/HCV screening in English or Spanish, access to stool deoxyribonucleic acid (DNA) testing, access to HCV antibody testing, and a cue to action (patient reminder card) during months 7-12.
WAVE 2: Clinic sites receive a customized electronic health record best practice alert pairing CRC and HCV screening with direct test ordering option and standard operating procedures for follow-up care for patients with an abnormal screening result and in need of treatment. Providers receive training and semi-annual feedback on CRC screening and HCV screening rates during months 13-18. Patients receive a combined education booklet with information about CRC/CRC screening and HCV infections/liver cancer/HCV screening in English or Spanish, access to stool DNA testing, access to HCV antibody testing, and a cue to action (patient reminder card) during months 13-18.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationMoffitt Cancer Center
Principal InvestigatorShannon M. Christy
